BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Human Longevity Inc.

Human Longevity Inc. Expands Role in Newborn Genome Sequencing with Strategic Acquisition of LifebankUSA from Celgene

January 28, 2016 By Cade Hildreth (CEO) Leave a Comment

Human Longevity Inc. Advances Leadership Role in Newborn Genome Sequencing with Strategic Acquisition of Stem Cell Banking from Celgene Cellular Therapeutics

In major news released today, Human Longevity, Inc. (HLI) announced that is is acquiring LifebankUSA, a cord blood, placental blood, and tissue bank owned by Celegene Cellular Therapeutics, a move that will position HLI to offer its newborn genome sequencing product in combination with stem cell banking services.

To learn more about the acquisition, read the full press release from Human Longevity, Inc. below.

Or, read our recent article exploring how this move will provide HLI with increased access to prenatal, neonatal, and maternal health markets, similar to the access that AMAG Pharmaceutical gained through its acquisition of Cord Blood Registry and PerkinElmer gained through its acquisition of ViaCord. [Read more…]

Filed Under: Cord Blood, HSCs, MSCs, Stem Cells Tagged With: CBR, cord blood, cord tissue, Human Longevity Inc., market news, press release, viacord

Human Longevity, Inc. to Expand Reach into Neonatal & Maternal Health Markets by Acquiring Celgene Owned LifebankUSA

January 28, 2016 By Cade Hildreth (CEO) Leave a Comment

Human Longevity, Inc. to Expand Reach into Neonatal & Maternal Health Markets by Acquiring Celegene Owned LifebankUSA

In major news released today, Human Longevity, Inc. (HLI) announced that is is acquiring LifebankUSA, a cord blood, placental blood, and tissue bank owned by Celgene Cellular Therapeutics.

Based in San Diego, CA, Human Longevity, Inc. is an innovative company that specializes in the use of whole genome sequence analysis, clinical imaging, and machine learning to extend health across a longer human lifespan. LifebankUSA, based in Cedar Knolls, NJ, is the “the only company that offers cord blood, placenta blood and tissue banking – and the first to release placenta-derived stem cells for a successful transplant.” Celgene Cellular Therapeutics (CCT), the parent company of LifeBankUSA, specializes in cell therapy and regenerative medicine products, using LifeBankUSA to source its cell therapy, organ and tissue products, several of which are now being explored in clinical trials (PDA001, PDA002, and others).

The move will position Human Longevity, Inc. to offers its newborn genome sequencing product in combination to its newly acquired stem cell banking services.
[Read more…]

Filed Under: Cord Blood, HSCs, MSCs, Press Releases, Stem Cells Tagged With: CBR, cord blood, cord tissue, Human Longevity Inc., placental, stem cells, viacord

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.